Skip to main content

Resmed Value Stock - Dividend - Research Selection

Resmed

ISIN: US7611521078 , WKN: 895878

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Are Wall Street Analysts Predicting ResMed Stock Will Climb or Sink?

2025-11-20
ResMed has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

1 Large-Cap Stock to Target This Week and 2 We Brush Off

2025-11-19
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

Diamond Hill Long-Short Strategy: Q3 2025 Longs And Shorts

2025-11-18
Diamond Hill Capital Management highlights Q3 long and short picks, favoring undervalued growth and trimming overvalued names. Explore their latest portfolio insights.

ResMed: Safe Bet For A Recession Environment

2025-11-17
Discover why ResMed is a top buy with strong fundamentals, robust cash flow, and dividend potential—ideal for recession-proof investing.

Resmed CEO Mick Farrell on new technologies, tariffs and AI

2025-11-17
The incoming AdvaMed chair talked about updates to Resmed’s products and how the company is handling competitive dynamics and tariffs.

Investing in ResMed (NYSE:RMD) five years ago would have delivered you a 21% gain

2025-11-16
ResMed Inc. ( NYSE:RMD ) shareholders might be concerned after seeing the share price drop 15% in the last quarter. On...

ResMed Inc. stock falls Friday, underperforms market

2025-11-14
ResMed Inc. stock falls Friday, underperforms market

Moat Stocks Climb In A Concentrated Market

2025-11-14
Moat Index outpaced the S&P 500 in October, driven by strong stock selection. Click here to read more.

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio

2025-11-14
INSIDE INFORMATIONREGULATED INFORMATION Correction and ReplacementNyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah’s Chairman and Management, and a convertible bond. This press release replaces the press release issued on November 13, 2025, at 10:11 pm CET / 4:11 pm ET in order to replace and correct the gross proceeds of the private placement and regi

Top Stock Reports for Exxon Mobil, Home Depot & NextEra Energy

2025-11-11
Exxon Mobil, Home Depot and NextEra Energy headline today's Zacks reports, each revealing key growth drivers and challenges shaping 2025 performance.